Stage IV Bladder Cancer: Clinical Trials

8 trials for Stage IV Bladder Cancer, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 completed, 2 terminated. 8 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 18Completed 6, Terminated 2
Phase 21Completed 1

Follow Stage IV Bladder Cancer: new trials by email Literature Review of Stage IV Bladder Cancer trials Research Report on Stage IV Bladder Cancer

Trials (filtered) newest first · largest first

All 8 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma
Enzyme Inhibitor Therapy, Laboratory Biomarker Analysis, Nivolumab - Lymphoma, Metastatic Malignant Solid Neoplasm
Phase 1CompletedRutgers, The State University of New Jersey142017-10-032023-12-06
Sirolimus, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Bladder Cancer
Cisplatin, Gemcitabine Hydrochloride, Sirolimus - Recurrent Bladder Carcinoma, Stage II Bladder Cancer
Phase 1 / Phase 2CompletedUniversity of Washington212013-10-012017-10-20
Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Biliary, Pancreatic, Urothelial, or Non-Small Cell Lung Cancer
gemcitabine hydrochloride, veliparib, diagnostic laboratory biomarker analysis - Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer
Phase 1TerminatedNational Cancer Institute (NCI)442011-01-012013-07-02
Neoadjuvant Intravesical Vaccine Therapy in Treating Patients With Bladder Carcinoma Who Are Undergoing Cystectomy
Recombinant Fowlpox-TRICOM Vaccine, Recombinant Fowlpox GM-CSF Vaccine Adjuvant, Therapeutic Conventional Surgery - Bladder Adenocarcinoma, Bladder Squamous Cell Carcinoma
Phase 1TerminatedNational Cancer Institute (NCI)212003-10-012014-12-23
Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction
erlotinib hydrochloride, laboratory biomarker analysis - Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma
Phase 1CompletedNational Cancer Institute (NCI)752001-12-012013-01-16
Decitabine in Treating Patients With Advanced Solid Tumors
decitabine, pharmacological study, laboratory biomarker analysis - Male Breast Cancer, Recurrent Bladder Cancer
Phase 1CompletedNational Cancer Institute (NCI)242001-12-012013-02-07
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
recombinant interleukin-12, ABI-007/carboplatin/trastuzumab - Advanced Adult Primary Liver Cancer, Anaplastic Thyroid Cancer
Phase 1CompletedNational Cancer Institute (NCI)151999-08-012013-02-28
Gene Therapy in Treating Patients With Advanced Bladder Cancer
Ad5CMV-p53 gene - Recurrent Bladder Cancer, Stage I Bladder Cancer
Phase 1CompletedNational Cancer Institute (NCI)241998-05-012013-01-23

Narrower conditions

Urinary Bladder Neoplasms (8)  ·  Carcinoma, Non-Small-Cell Lung (4)  ·  Breast Neoplasms (3)  ·  Breast Neoplasms, Male (3)  ·  Pancreatic Neoplasms (3)  ·  Squamous Cell Carcinoma of Head and Neck (3)  ·  Anus Neoplasms (2)  ·  Carcinoma, Hepatocellular (2)  ·  Carcinoma, Ovarian Epithelial (2)  ·  Carcinoma, Renal Cell (2)  ·  Colonic Neoplasms (2)  ·  Esophageal Neoplasms (2)  ·  Melanoma (2)  ·  Prostatic Neoplasms (2)  ·  Rectal Neoplasms (2)

Broader conditions

Female Urogenital Diseases (8)  ·  Female Urogenital Diseases and Pregnancy Complications (8)  ·  Male Urogenital Diseases (8)  ·  Neoplasms (8)  ·  Neoplasms by Site (8)  ·  Urinary Bladder Diseases (8)  ·  Urogenital Diseases (8)  ·  Urogenital Neoplasms (8)  ·  Urologic Diseases (8)  ·  Urologic Neoplasms (8)  ·  Bronchial Neoplasms (4)  ·  Carcinoma, Bronchogenic (4)  ·  Lung Diseases (4)  ·  Lung Neoplasms (4)  ·  Neoplasms by Histologic Type (4)

Interventions

Cisplatin (2)  ·  Gemcitabine (2)  ·  1,2-diaminocyclohexaneplatinum II citrate (1)  ·  Cystectomy (1)  ·  Decitabine (1)  ·  Erlotinib Hydrochloride (1)  ·  Interleukin-12 (1)  ·  Interleukin-12 Subunit p35 (1)  ·  Nivolumab (1)  ·  Platinum (1)  ·  Sirolimus (1)  ·  Trastuzumab (1)  ·  advexin (1)  ·  pembrolizumab (1)  ·  veliparib (1)

Sponsors

National Cancer Institute (NCI) (6)  ·  Rutgers, The State University of New Jersey (1)  ·  University of Washington (1)

Countries

United States (8)

Top investigators

Antonius Miller (1)  ·  Biren Saraiya (1)  ·  Jeffrey Weber (1)  ·  Lance Pagliaro (1)  ·  Leonard Appleman (1)  ·  Robert Montgomery (1)  ·  Robert Weiss (1)  ·  William Carson (1)

Results publications

PMID 35780243, PMID 39462179

NIH funding

P30CA072720 (2), P30CA015704 (1), R21CA076233 (1), U01CA062505 (1), U01CA076576 (1), U01CA099168 (1), U01CA132194 (1), U10CA031946 (1)